Healthcare Services

Diabetic Neuropathy Market to Reach $10.13B by 2030 with Steady Growth

April 21, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Diabetic Neuropathy Market Grow Between 2026 And 2030?

The diabetic neuropathy market has demonstrated robust expansion recently. Its size is anticipated to expand from $6.21 billion in 2025 to $6.83 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.0%. Factors contributing to its historical growth include the widespread prevalence of long-term uncontrolled diabetes, delayed identification of nerve damage, a scarcity of effective treatment options, a reliance on pain management strategies, and increasing patient discomfort.

The diabetic neuropathy market is projected to experience significant expansion in the coming years, anticipated to reach a valuation of $10.14 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.4%. Several factors contribute to this projected growth, including the advancement of specific neuropathy drugs, broader availability of early diagnostic instruments, a rise in patient screening, the proliferation of specialized neurology clinics, and a greater desire for enhanced quality of life. Key trends expected during this period involve a surge in the utilization of neuropathic pain treatments, heightened emphasis on identifying nerve damage early, the proliferation of combined drug treatments, an increasing embrace of symptom control strategies, and improved patient understanding and diagnostic frequency.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/diabetic-neuropathy-global-market-report

Which Factors Are Influencing The Growth Of The Diabetic Neuropathy Market?

The anticipated increase in diabetes cases is poised to propel the expansion of the diabetic neuropathy market in the future. Diabetes is a chronic condition characterized by the body’s impaired ability to properly utilize and store glucose (a form of sugar). This condition develops either when the body produces insufficient insulin—a hormone crucial for blood sugar control—or when it fails to use insulin efficiently. Diabetic neuropathy refers to nerve damage that can affect individuals with diabetes, manifesting in various types of nerve impairment and resulting in diverse symptoms. For example, data from April 2025 by the International Diabetes Federation, a Belgium-based global not-for-profit federation of national diabetes associations, indicated that approximately 589 million adults aged 20–79 globally had diabetes, a figure expected to climb to 853 million by 2050. Consequently, the growing incidence of diabetes is a key factor driving the expansion of the diabetic neuropathy market.

Which Segments Define The Diabetic Neuropathy Market Segment Structure?

The diabetic neuropathy market covered in this report is segmented –

1) By Disorder: Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy

2) By Drug Class: Analgesics, Anti-Depressants, Anti-Convulsants, Other Drug Classes

3) By Treatment: Drug Treatment, Radiotherapy, Physiotherapy, Other Treatments

4) By Distribution Channel: Online Distribution, Offline Distribution

5) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Peripheral Neuropathy: Distal Symmetric Neuropathy, Mononeuropathy, Polyneuropathy

2) By Autonomic Neuropathy: Cardiovascular Autonomic Neuropathy, Gastrointestinal Autonomic Neuropathy, Genitourinary Autonomic Neuropathy

3) By Proximal Neuropathy: Diabetic Amyotrophy, Lumbosacral Plexus Neuropathy

4) By Focal Neuropathy: Cranial Neuropathy, Cervical Radiculopathy

Which Trends Are Influencing Demand In The Diabetic Neuropathy Market?

Leading firms within the diabetic neuropathy market are developing cutting-edge products, like neuromodulation therapy devices, aiming to improve treatment choices for individuals experiencing chronic pain linked to diabetic neuropathy. These neuromodulation devices provide non-invasive remedies for diabetic neuropathy, working by adjusting nerve activity to alleviate discomfort, enhance nerve function, and encourage recovery in those with diabetic nerve damage. As an example, in January 2024, Neuralace Medical, Inc., a US-based company specializing in non-drug pain management, secured approval from the Food and Drug Administration (FDA), a US federal agency, for its Axon Therapy intended for Chronic Painful Diabetic Neuropathy. The Axon Therapy device is specifically engineered to address chronic painful diabetic neuropathy (CPDN). This novel therapy employs neuromodulation methods to offer relief from pain related to diabetic neuropathy, representing a notable leap forward in pain management strategies for patients affected by this ailment. This clearance emphasizes the device’s safety and effectiveness, enabling Neuralace to proceed with its commercial launch and broaden access to efficacious treatment solutions for individuals impacted by CPDN.

Who Are The Established Players Within The Diabetic Neuropathy Market?

Major companies operating in the diabetic neuropathy market are Pfizer Inc., Eli Lilly and Company, Daiichi Sankyo Company Limited, Johnson & Johnson, Depomed Inc., F. Hoffmann-La Roche AG, NeuroMetrix Inc, Lupin Limited, Novartis AG, Boehringer Ingelheim, Regenacy Pharmaceuticals Inc., Merck & Co. Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Merck KGaA, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Zydus Cadila, Genentech Inc.

Get The Full Diabetic Neuropathy Market Report:

https://www.thebusinessresearchcompany.com/report/diabetic-neuropathy-global-market-report

Which Region Is The Largest In The Diabetic Neuropathy Market?

North America was the largest region in the diabetic neuropathy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the diabetic neuropathy market during the forecast period. The regions covered in the diabetic neuropathy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Diabetic Neuropathy Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/diabetic-neuropathy-global-market-report

Browse Through More Reports Similar to the Global Diabetic Neuropathy Market 2026, By The Business Research Company

Non Proliferative Diabetic Retinopathy Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-proliferative-diabetic-retinopathy-global-market-report

Peripheral Neuropathy Market Report 2026

https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report

Diabetic Retinopathy Market Report 2026

https://www.thebusinessresearchcompany.com/report/diabetic-retinopathy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795